Study of Adebrelimab with SHR-8068 and chemoradiation before surgery for rectal cancer
Part of Cancer clinical trials.
This trial tests whether adding two immunotherapy drugs (adebrelimab and SHR-8068) to standard chemoradiation before surgery can improve outcomes for adults with locally advanced rectal cancer that can be surgically removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have locally advanced rectal cancer that can be surgically removed.
- You have not had any prior treatment for rectal cancer (like chemotherapy, radiation, or surgery).
- Your general health is good enough to walk around and care for yourself (ECOG 0-1).
- If you could become pregnant, you agree to use birth control for 6 months after treatment, and you are not pregnant or breastfeeding.
- You do not have cancer that has spread to other parts of the body or to lymph nodes in the pelvis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called SHR-1701 combined with standard chemotherapy and radiation for people with locally advanced rectal cancer. The goal is to shrink the tumor before surgery, making it easier to remove completely.
This trial tests a combination of a PD-L1 inhibitor (adebrelimab), short-course radiation, and chemotherapy given before surgery for locally advanced rectal cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests a new combination of three drugs for people with advanced colorectal cancer that has not responded to previous treatments. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests whether a short course of radiation followed by an immunotherapy drug (PD-L1 inhibitor) plus chemotherapy works as well as or better than a longer radiation course for locally advanced rectal cancer. The goal is to shrink tumors before surgery.
This trial tests whether adding a new immunotherapy drug (adebrelimab) to standard chemoradiation helps treat locally advanced cervical cancer better than chemoradiation alone.
This trial tests a combination of radiation therapy, a chemotherapy drug called NALIRIFOX, and an immunotherapy drug called adebrelimab for rectal cancer that has grown into nearby tissue or lymph nodes. The goal is to see if this combination helps shrink the tumor before surgery and improves outcomes.
Hear when a new Locally Advanced Resectable Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.